Overcoming Secondary Loss of Response to Infliximab in Patients With Ulcerative Colitis With the Use of Mesenchymal Stromal Cells

Knyazev Oleg,1 Lishchinskaya Anatoly2, Konoplyannikov Anatoly3, Knyazevam Anna4, Fedeva Nina,5 Kolakow Dmitriy,6 Babayan Anatii,7 Zyuganova Mariya8, Parfenov Alina9,10,11 Moscow Clinical Scientific Center Named After A. S. Lomonosov, Moscow, Russia.12 Medical Radiological Research Center Center Named After A. Tsykh, Obninsk, Russia.

BACKGROUND: Long-term experience with infliximab (IFX) shows that within a year, 20–30% of patients with ulcerative colitis (UC) develop acquired drug resistance (secondary inefficiency). Aim: To establish the possibility of overcoming the secondary inefficiency of IFX in UC patients using mesenchymal stromal cells (MSCS).

METHODS: In the IBD treatment department, the clinical status of 84 UC patients receiving IFX therapy was evaluated. Secondary loss of response was registered in 28 UC patients, which required optimization of IFX therapy. Twelve patients (group 1), in order to overcome the secondary loss of response, were administered MSCS three times every 4 weeks. 16 patients with UC (group 2) received standard optimized IFX therapy. The effectiveness of therapy was evaluated after 12 weeks of therapy (reduction of the Mayo score) and normalization of laboratory parameters (erythocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin, FCP). The comparative analysis was carried out using the method of four-field tables using nonparametric statistical criteria.

RESULTS: In 10 (83.3%) of 12 patients of group 1, a significant positive dynamic was observed after 12 weeks: a decrease in the Mayo index and normalization of laboratory parameters (ESR, CRP, hemoglobin, FCP). However, 12 patients from group 2 were transferred to therapy with other anti-TNF-α drugs and drugs with a different mechanism of action (HR = 0.122, 95% CI 0.019–0.782, P = 0.043).

CONCLUSION: The use of mesenchymal stromal cells of the bone marrow helps to overcome the secondary loss of response to infliximab in patients with ulcerative colitis.

Dependence of the Duration of Clinical Remission in Crohn’s Disease From the Frequency of Introduction of Mesenchymal Stromal Cells

Knyazev Oleg,1 Knyazevam Anna2, Fedeva Nina,3 Babayan Anatii4, Lishchinskaya Anatoly5, Kolakow Dmitriy6, Lid Irina7, Zyuganova Mariya8, Voselov Alexey9, Shikunza Tatiana10, Demchenko Alexandra11, Parfenov Alina12, Moscow Clinical Scientific Center Named After A. S. Lomonosov, Moscow, Russia.13 Research Institute of Health Organization and Management, Moscow, Russia.

BACKGROUND: Anti-cytokine therapy with anti-TNF-α drugs contributes to the achievement of persistent remission of Crohn’s disease (CD). Allogeneic mesenchymal stromal cells (MSC) of the bone marrow are also used for the treatment of CD. Objective: to evaluate the duration of remission of CD in the context of mesenchymal stromal cells (MSC) therapy of the bone marrow, depending on the frequency of MSC administration.

METHODS: 76 patients with luminal CD (terminal ileum, colitis, and ileocolitis) were divided into two groups. The first group of patients aged 19 to 58 years (Me=29) received culture of MSCs according to the scheme: 0-1-2-12-26-52 weeks, then annually 2 times a year. The second group of patients with CD (n = 42) aged 20 to 62 years (Me=28) received culture of MSCs according to the scheme: 0-1-2-12-26-52 weeks to achieve remission within one year. The effectiveness of therapy was evaluated at 12, 24, 36, and 48 months after the start of therapy using the Harvey-Bradshaw index.

RESULTS: During 12 months of follow-up, 4/34 patients (11.76%) relapsed among patients in first group. In second group, relapse occurred in 5/42 (11.9%) (HR = 0.83, 95% CI 0.328–2.19, P = 0.73). At 24 months, 6/34 patients (17.6%) relapsed in the first group, the group of patients with CD relapsed in 11/42 (26.3%) (HR = 0.67, 95% CI 0.278–1.634, P = 0.37). After 36 months, the disease relapsed in 16/74 patients in the first group (21.6%). In the second group, relapse was in 10/42 (42.8%) (HR = 0.48, 95% CI 0.228–1.014, P = 0.038). After 48 months, in the first group receiving MSCs, relapse occurred in 3/4 (76.9%). In the second group, relapse occurred in 22/42 (52.4%) (HR = 0.50, 95% CI 0.269–0.949, P = 0.021). At 60 months, 10/34 (29.4%) relapsed in the first group. In the second group, relapse occurred in 24/42 (55.7% (HR = 0.469, 95% CI 0.250–0.864, P = 0.007).

CONCLUSION: The duration of clinical remission in CD patients with luminal CD depends on the frequency of administration of MSC.

Anti-TNF-Therapy-Induced Leukocytoclastic Vasculitis: A Rare Complication in IBD Patients

Parra Rocio1, Costa Junior 2, Costa Liliana3, Luna Junior Sergio4, Neto Manuel5, Medeiros Tereza6, Faria Francisco7, Fasotta Marly8, Feres Oscar9, Rocha Jos Io9,10,11,12

1Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil; 2Federal University of Juiz de Fora, Juiz de Fora, Brazil; 3UFESP, Juiz de Fora, Brazil; 4UNIFESP, São Paulo, Brazil; 5Universidade Federal de São Paulo, São Paulo, Brazil; 6University of São Paulo, São Paulo, Brazil; 7Santa Casa de São Paulo; 8Hospital Israelita Albert Einstein, São Paulo, Brazil; 9University Federal de São Paulo/ Hospital Israelita Albert Einstein, São Paulo, Brazil; 10Faculdade de Medicina Do ABC, Santo André, Brazil; 11Universidad Federal de Minas Gerais, UFMG, Belo Horizonte, Brazil.

BACKGROUND: Real world data regarding long-term effectiveness and safety of ustekinumab (UST) for the treatment of Crohn’s disease (CD) is lacking in South America. We report the outcomes of a Brazilian multicentre retrospective cohort in patients with moderate-to-severe CD treated with UST in a real-world setting.

METHODS: Between November 2017 and December 2019, a retrospective study was performed including patients from 12 inflammatory bowel disease (IBD) academic medical centers diagnosed with moderately to severely active CD starting on UST (weight-based single IV infusion dose followed by 90 mg subcutaneous maintenance dose administered 8 weeks after the initial intravenous dose) over 8 weeks thereafter (5.1%). The primary outcome was clinical remission (Harvey-Bradshaw index ≤ 4) at 16 weeks. Secondary outcomes included clinical remission at weeks 24 and 56, clinical response at weeks 8 and 16 (HBI decrease ≥ 3), biochemical remission at week 16 (C-reactive protein [CRP] normalization in patients with elevated CRP baseline levels), corticosteroid-free remission and drug discontinuation.

RESULTS: Among 241 patients included (mean age 39.9 years old), 86% had been previously exposed to at least one biologic, 61.9% had been treated with only one biologic agent, and 141 (68.1%) with two or more biologics. Twenty-five percent (50/204) received combined therapy with immunomodulators. Corticosteroids were administered during induction in 97 patients (57.7%, 97/170). At baseline, mean HBI was 10.3 (range 5-23) and mean CRP was 20.5 (range 0-125). Clinical response at week 8 was observed in 66.7% of patients (144/216). In non-responder imputation (NRI) analysis, clinical remission was achieved in 60.2%, 51.4% and 24.1% at week 16, 24 and 56 respectively. Biochemical remission was achieved in 61.9% of patients (114/186). Corticosteroid-free remission was achieved in 59.6% of patients at their last follow up. A total of 39 patients (18.2%) interrupted their therapy and the main reasons for discontinuation were loss of response / disease progression (35.9%), primary failure (25.6%), lack of access / no reimbursement (17.9%), pregnancy (15.4%) and abandonment of treatment (5.1%). HBI higher than 9 at baseline, previous exposure to anti-TNF and penetrating disease were associated with lower rates of clinical remission. No new safety signals were observed.

CONCLUSION: This is the first study to show the long-term safety and real-world effectiveness of UST in a cohort of moderate-to-severe CD patients in Brazil. This study confirms the previous reported effectiveness and long-term maintenance of response of UST in CD patients exposed to biological therapy, especially to anti-TNF agents. UST was well tolerated, and no new safety signals were identified in this study.

Antibiotic Bone Marrow Transplantation in Refractory Crohn’s Disease: A Case Report

Bintu Justice1, Akkinson Ken2,3

1University of British Columbia, Vancouver Fraser Medical Program, Vancouver, Canada; 2Royal Columbian Hospital, Fraser Health Authority, New Westminster, Canada.

The American Journal of GASTROENTEROLOGY

VOLUME 115 | SUPPLEMENT | DECEMBER 2020

www.amjgastro.com

Copyright © 2020 By The American College of Gastroenterology. Unauthorized reproduction of this article is prohibited.